<?xml version="1.0" encoding="utf-8"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="en"><title>News on Sanofi-Aventis Sa</title><link href="http://guidetoinsomnia.com/topic/sanofi-aventis-sa" rel="alternate"></link><id>http://guidetoinsomnia.com/topic/sanofi-aventis-sa</id><updated>2010-10-24T15:17:19Z</updated><entry><title>Sanofi Ends Development Of Insomnia, Clot Drugs</title><link href="http://guidetoinsomnia.com/insomnia/sanofi-ends-development-insomnia-clot-drugs-3070316a" rel="alternate"></link><updated>2010-10-24T15:17:19Z</updated><author><name>Drugs.com</name></author><id>tag:guidetoinsomnia.com,2010-10-24:/insomnia/sanofi-ends-development-insomnia-clot-drugs-3070316a/</id><summary type="html">...</summary><category term="Clinical Trials"></category><category term="Medical Treatments and Procedures"></category><category term="Medical Drug Therapy"></category><category term="Insomnia"></category><category term="Health Care Services Sector"></category><category term="Biotechnology Sector"></category><category term="Pharmaceuticals Sector"></category><category term="United States"></category><category term="Europe"></category><category term="Tennessee"></category><category term="Food and Drug Administration"></category><category term="European Medicines Agency"></category><category term="Icy Hot Pain Reliever"></category><category term="Ambien"></category><category term="Chattem Inc."></category><category term="Sanofi-Aventis SA"></category><category term="Chattanooga"></category><category term="EMEA Committee for Medicinal Products for Human Use"></category><category term="Gold Bond Medicated Powder"></category><category term="Cardiovascular Medicine"></category><category term="Sleeping and Sleep Disorders"></category><category term="European Medicines Agency for DuoPlavin"></category></entry><entry><title>Ignoring Insomnia Costs America $42 Billion a Year</title><link href="http://guidetoinsomnia.com/insomnia/ignoring-insomnia-costs-america-42-billion-year-3010110a" rel="alternate"></link><updated>2010-10-24T09:14:39Z</updated><author><name>Drugs.com</name></author><id>tag:guidetoinsomnia.com,2010-10-24:/insomnia/ignoring-insomnia-costs-america-42-billion-year-3010110a/</id><summary type="html">...</summary><category term="Insomnia"></category><category term="Health Care Services Sector"></category><category term="United States"></category><category term="Sanofi-Aventis SA"></category><category term="Robert Goldberg"></category><category term="Peter Pitts"></category><category term="Sleeping and Sleep Disorders"></category></entry><entry><title>What to watch in 2009</title><link href="http://guidetoinsomnia.com/insomnia/watch-2009-2973516a" rel="alternate"></link><updated>2010-10-23T19:02:31Z</updated><author><name>Modern Medicine</name></author><id>tag:guidetoinsomnia.com,2010-10-23:/insomnia/watch-2009-2973516a/</id><summary type="html">...</summary><category term="Migraine Medications"></category><category term="Migraine Treatment and Prevention"></category><category term="Migraines and Side Effects"></category><category term="Clinical Trials"></category><category term="Vascular Disorders"></category><category term="Venous Disorders"></category><category term="Internal Medicine"></category><category term="Metabolic Disorders"></category><category term="Diabetes"></category><category term="Respiratory Medicine"></category><category term="Asthma"></category><category term="Chronic Obstructive Pulmonary Disease"></category><category term="Insomnia"></category><category term="Mental Health"></category><category term="Mental Health Treatments"></category><category term="Technology"></category><category term="Medical Technology"></category><category term="Biotechnology Sector"></category><category term="Pharmaceuticals Sector"></category><category term="Kansas City"></category><category term="Food and Drug Administration"></category><category term="GlaxoSmithKline plc"></category><category term="Schering-Plough Corporation"></category><category term="Advair"></category><category term="AstraZeneca Group"></category><category term="Novartis AG"></category><category term="Bristol-Myers Squibb Company"></category><category term="Botox"></category><category term="Pfizer Inc."></category><category term="Allergan Inc."></category><category term="Cialis"></category><category term="Ambien"></category><category term="Sanofi-Aventis SA"></category><category term="Plavix"></category><category term="Genzyme Corporation"></category><category term="Novo Nordisk AS"></category><category term="Medco Health Solutions Inc."></category><category term="Boehringer Ingelheim GmbH"></category><category term="H. Lundbeck AS"></category><category term="United Therapeutics Corporation"></category><category term="Remodulin"></category><category term="MannKind Corporation"></category><category term="Cardiovascular Medicine"></category><category term="Silenor"></category><category term="Somaxon Pharmaceuticals Inc."></category><category term="Effient"></category><category term="Multaq"></category><category term="Academy of Managed Care Pharmacy"></category><category term="Blood Clots and Embolisms"></category><category term="Mental Health Drug Therapy"></category><category term="Onglyza"></category><category term="Antidepressants"></category><category term="Keith Bradbury"></category><category term="Brian Kolling"></category></entry></feed>
